155 related articles for article (PubMed ID: 35778352)
1. COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.
Hervig TA; Flesland Ø; Nissen-Meyer LSH
Transfus Apher Sci; 2022 Aug; 61(4):103487. PubMed ID: 35778352
[TBL] [Abstract][Full Text] [Related]
2. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
[TBL] [Abstract][Full Text] [Related]
6. [Value of convalescent plasma in the therapy of COVID-19].
Körper S; Seifried E; Schrezenmeier H
Dtsch Med Wochenschr; 2023 Mar; 148(7):423-426. PubMed ID: 36940693
[TBL] [Abstract][Full Text] [Related]
7. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
[TBL] [Abstract][Full Text] [Related]
8. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
10. Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.
Hassan S; West KA; Conry-Cantilena K; De Giorgi V
Transfusion; 2022 Feb; 62(2):483-492. PubMed ID: 34778974
[No Abstract] [Full Text] [Related]
11. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
13. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.
Wendel S; Land K; Devine DV; Daly J; Bazin R; Tiberghien P; Lee CK; Arora S; Patidar GK; Khillan K; Smid WM; Vrielink H; Oreh A; Al-Riyami AZ; Hindawi S; Vermeulen M; Louw V; Burnouf T; Bloch EM; Goel R; Townsend M; So-Osman C
Vox Sang; 2021 Sep; 116(8):872-879. PubMed ID: 33772791
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities.
Al-Riyami AZ; Schäfer R; van den Berg K; Bloch EM; Estcourt LJ; Goel R; Hindawi S; Josephson CD; Land K; McQuilten ZK; Spitalnik SL; Wood EM; Devine DV; So-Osman C
Vox Sang; 2021 Jan; 116(1):88-98. PubMed ID: 32542847
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 convalescent plasma from Norwegian blood donors.
Nissen-Meyer LSH; Hervig T; Fevang B; Norheim G; Kran AB; Vaage JT; Flesland Ø
Tidsskr Nor Laegeforen; 2022 Jun; 142(9):. PubMed ID: 35699539
[TBL] [Abstract][Full Text] [Related]
17. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
19. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
20. Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.
Hähnel V; Peterhoff D; Bäuerlein V; Brosig AM; Pamler I; Johnson C; Bica A; Totir M; Ossner T; Stemmer B; Toelge M; Schütz A; Niller HH; Schmidt B; Wagner R; Gessner A; Burkhard R; Offner R
PLoS One; 2020; 15(12):e0243967. PubMed ID: 33351831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
